Context: Insulin-like factor 3 (INSL3) is produced by the Leydig cells, and in adults, its secretion is dependent on the state of differentiation of these cells, which, in turn, is dependent on LH. However, the secretion and regulation of INSL3 during puberty is unknown.
I NSULIN-LIKE FACTOR 3 (INSL3), previously known as relaxin-like factor, is a member of the relaxin-insulin hormone family and is a major new circulating hormone in the male. This peptide is produced almost exclusively by the Leydig cells of the testis and affects testicular descent during fetal development by acting on gubernaculum via its specific receptor, leucine-rich repeat-containing G protein-coupled receptor 8 (LGR8) (1) (2) (3) (4) . Mutations of INSL3 and/or LGR8 genes have been associated also with human cryptorchidism (5, 6) .
In the mouse and rats, Insl3 is highly expressed in the fetal testis but is down-regulated after birth before expression is again up-regulated at puberty (7, 8) . Other than the role in testicular descent, recent data suggested additional yet unidentified endocrine and paracrine actions of INSL3 in adults. In fact, INSL3 is expressed also in adult-type Leydig cells (7, 9 -13) , and LGR8 is expressed in germ cells of the testis and ovary (12, 14) and in many other tissues, including kidney, muscle, thyroid, pituitary gland, and bone marrow (1, 2, 15) . Furthermore, INSL3 is secreted into general circulation in postpubertal males (15) (16) (17) (18) (19) . In particular, the availability of a new commercial RIA kit (Phoenix Pharmaceuticals, Belmont, CA) (15) and the development of a semiquantitative time-resolved fluorescence immunoassay (18) recently allowed clarification of many aspects of INSL3 production and regulation in adults (15, (17) (18) (19) . These studies showed high INSL3 serum concentrations in the adults (500 -1000 pg/ml), demonstrating that this peptide represents a male-specific hormone produced constitutively, once Leydig cells are mature. Its production is dependent on the state of differentiation of the Leydig cells, which in turn is dependent on LH, and INSL3 production is reduced in situations of undifferentiated or altered Leydig cell status. These data have proposed the use of INSL3 as a specific marker of Leydig cell differentiation status, and INSL3 has been suggested to be even more sensitive than testosterone to impaired Leydig cell function (15, 18) , even if definitive evidence is lacking.
The secretion and regulation of INSL3 during puberty in humans is unknown. In this study, we evaluated INSL3 concentrations in 75 normal boys in relation to age, pubertal stages, and LH, FSH, and testosterone levels. With this study, we now have more detailed information on the dynamics of this new testicular hormone.
tion. All subjects and their parents were asked for and provided their informed consent.
The study design included 75 healthy male subjects aged 9.5-17.5 yr, homogeneously distributed by their pubertal development into five groups of 15 according to Tanner (20) . Pubertal stage assignment was performed by the same two physicians. The subjects were recruited from January to December 2005 among those who came under our observation for clinical assessment of pubertal development and were at the normal stage of pubertal development for their chronological age. The sign for clinical onset of puberty (G2) was considered as testicular volume more than 3 ml. Exclusion criteria were acute and chronic pathologies, in particular uroandrological pathologies such as cryptorchidism, varicocele, orchiepididymitis, and endocrine pathologies as evaluated by normal thyroid hormones and TSH, GH, IGF-I, and cortisol concentrations. None of the recruited subjects was taking medications. Testicular volume was measured using the Prader orchidometer.
Hormone determinations
Serum concentrations of INSL3 in all subjects were measured in duplicate by RIA (Phoenix Pharmaceuticals), as previously reported (15) . Intra-and interassay coefficients of variation were less than 5 and 10%, respectively. The lower detection limit of the INSL3 RIA kit, determined by the linear range of the standard curve, was established to be 1 pg/tube (10 pg/ml), and the range of the assay is 1-128 pg/tube (10 -1280 pg/ml) (15) . LH and FSH were measured by immunoradiometric assay and testosterone by RIA with commercial kits (Adaltis Italia, Bologna, Italy), with detection limits of 0.1 IU/liter, 0.2 IU/liter, and 0.1 nmol/liter, respectively. Inter-and intraassay coefficients of variations were less than 10 and 5% (LH), less than 5 and 5% (FSH), and less than 10 and 10% (testosterone) for our laboratory. Blood samples were obtained in all subjects between 0800 and 0900 h. 
Statistical analysis
If a measured hormone concentration was below the limit of detection for the assay, it was expressed as the limit of detection. In general, nonparametric statistics were used because most data did not have a Gaussian distribution. Descriptive data are expressed as median and 95% confidence intervals of the median. The differences in hormone levels between the different pubertal stages were tested with a Wilcoxon's rank sum test. Correlation coefficients were calculated between INSL3 and FSH, LH, and testosterone by regression. Statistical analysis was performed with the open-source statistical software R (http:// cran.r-project.org). P values (two-sided) of Ͻ0.05 were regarded as significant.
Results
The individual serum INSL3, LH, FSH, and testosterone concentrations and the mean testicular volume are shown in relation to age in Fig. 1 . The median and 95% confidence intervals of the results grouped according to stage of puberty are shown in Table 1 , whereas the individual results per stage of puberty are shown in Fig. 2 . The serum levels of LH, FSH, and INSL3, but not of testosterone, significantly increased between stages 1 and 2. All measured hormones then significantly increased between stages 2 and 3 of puberty. LH, INSL3, and testosterone, but not FSH, increased significantly also between stages 3 and 4. No differences were seen for all measured hormones between stages 4 and 5. Therefore, the levels of INSL3 increased progressively throughout puberty in parallel with LH and FSH until stage 4, when INSL3 concentrations seemed to reach a plateau. INSL3 plasma concentrations at pubertal stages 4 and 5 did not reach adult levels (mean levels, 562.3 pg/ml; range, 310.1-908.5 pg/ml) (15), whereas FSH, LH, and testosterone reached adult levels by stage 4.
Positive significant correlations were found between INSL3 and LH for all pubertal stages [P Ͻ 0.05 in stages 1 (r ϭ 0.52), 2 (r ϭ 0.47), and 3; P Ͻ 0.01 in stages 4 (r ϭ 0.80) and 5 (r ϭ 0.57)] (data not shown). Positive significant correlation between INSL3 and LH (P Ͻ 0.001) was also observed when all 75 subjects were grouped (Fig. 3) . A positive significant correlation between INSL3 and testosterone was observed only in stage 3 of puberty (P Ͻ 0.05; r ϭ 0.50), whereas positive correlations between INSL3 and FSH were observed in stages 4 (P Ͻ 0.05; r ϭ 0.55) and 5 (P Ͻ 0.05; r ϭ 0.64) (data not shown).
Discussion
Animal data initially suggested that the production and secretion of INSL3 from the Leydig cells are dependent on human chorionic gonadotropin (hCG)/LH (7, 12, 13) . Recent evidence confirmed these reports also in adult humans: 1) patients with hypogonadotropic hypogonadism have very low INSL3 concentrations, comparable to those found in women (15, 18) ; 2) treatment of men with hypogonadotropic hypogonadism with hCG produced an increase in INSL3 concentrations (15, 18) ; and 3) treatment of gonadotropinsuppressed men with hCG induced an increase in INSL3 levels (15, 19) . The present study is the first that analyzes INSL3 concentrations during normal puberty and adds evidence for an LH-dependent INSL3 production also during puberty. Furthermore, this study confirms that INSL3 secretion is not affected by testosterone. In conjunction with previous reports on mRNA and protein expression in animal models (7, 8, 13, 21) , we have now more detailed information on the physiological dynamics of serum INSL3 and Leydig cell differentiation during puberty. INSL3 concentrations demonstrate a progressive increase throughout puberty that seems to be dependent on the differentiating action of LH on the Leydig cells. Similar to that found in adults (15, 18, 19) , serum INSL3 is therefore a marker of Leydig cell differentiation and function. However, in contrast with LH, FSH, and above all testosterone, INSL3 plasma concentrations at the end of puberty did not reach adult levels. A prolonged exposure to LH seems therefore necessary to fully differentiate the Leydig cells. In other words, these data suggest that during puberty, increasing levels of LH fully stimulate steroidogenesis, and thus testosterone secretion to adult levels, whereas the differentiation effect of LH on the Leydig cells, and thus INSL3 secretion, is incomplete at the end of puberty. These data fit well with the current knowledge of the triphasic pattern of Leydig cell development (22) . Postnatally, fetal Leydig cells are replaced by a population of neonatal Leydig cells, which remain relatively inactive until puberty. During the first stages of puberty, the pulsatility and increase in LH levels determine the activation of steroidogenesis with the consequent rise in testosterone concentration, and then adult-type Leydig cells completely differentiate (22, 23) . It is important to note, however, that the different pattern of secretion of INSL3 and testosterone from the Leydig cells may also be related to the differences between steroid and peptide synthesis and regulation. Taken together, these data suggest that during both pubertal development and adulthood, testosterone and INSL3 provide different information on the status of the Leydig cells. Testosterone better reflects the steroidogenic activity that is acutely sensitive to LH, whereas INSL3 seems to be uncoupled from this rapid stimulation of steroidogenesis and better reflects the differentiation status of the Leydig cells. This is in accordance with the finding that in adult-type Leydig cells, only testosterone and not INSL3 secretion is acutely responsive to LH and that after long-term treatment with hCG in gonadotropin-suppressed men, INSL3 did not recover to the same degree as testosterone (19, 24) . All these data highlight that INSL3 is a more sensitive marker of the status of Leydig cell differentiation and that it is more sensitive to Leydig cell impairment than testosterone.
Although Leydig cell development in humans is quite different from rodents, our findings on INSL3 concentrations during puberty expand the knowledge on this hormone from previous animal data. Insl3 mRNA is first detectable at embryonic d 13.5 in the mouse concomitant with the first determination of the fetal Leydig cell phenotype and increases in expression level to be maximal in the fetal Leydig cells in the immediate perinatal period. This temporal expression is coordinated with the major function of Insl3, which is to stimulate testicular descent by action on the gubernaculum (25, 26) . Insl3 is then down-regulated concomitant with the involution of the fetal Leydig cells (7, 21 ). Insl3 mRNA and protein then increase through puberty in a differentiationdependent manner concomitant with the establishment of the pituitary-gonadal axis (7) . In particular, Insl3 protein increases slowly between d 20 and 30 (corresponding to the mid-end of puberty), initially with a punctuate staining within the Leydig cells. Only after d 30 does the punctuate staining pattern give way to a more homogeneous distribution, similar to that seen in the adult mouse testis (7) . Similar results have also been obtained recently in rats (8) . INSL3 is therefore a hormone whose production reflects the differentiation status of the Leydig cells in a different way in the fetal and adult-type Leydig cells. Within adult-type Leydig cells, INSL3 is expressed under the differentiation effect of LH, whereas within the fetal Leydig cells, it is expressed in a fashion independent of an active pituitary-gonadal axis.
The dynamics of mouse and rat Insl3 production is therefore very similar to that seen in the present study in humans. Interestingly, treatment of hpg mouse with hCG induced an increase in Insl3 mRNA already by d 3 of treatment but only at 12 d was a punctuate INSL3 immunostaining evident in less than half of the Leydig cells (7) . Again, these data are in accordance with the INSL3 concentrations found in our study at the end of puberty, which are at intermediate levels between prepubertal age and adulthood.
In addition to the prenatal, and probably principal, role for INSL3 in testicular descent, postnatally expressed INSL3 has been suggested to exert paracrine (protection of germ cell apoptosis) (12, 14) and endocrine functions (based on the high circulating INSL3 levels and the expression of its receptor LGR8 in various human tissues) (1, 2, 15, 18, 19) . The finding of increasing INSL3 production during pubertal development concomitant with the increase in testicular volume and the establishment of a full spermatogenesis further suggests a role for this hormone in the adult testis related to male germ cell development/survival. Furthermore, during adulthood, INSL3 may be used as a marker of the differentiation and functional status of the Leydig cells. Its expression is reduced, for example, when these cells are dedifferentiated to become hyperplastic or neoplastic (27) , when they involute in the aging rat (28), when they seasonally dedifferentiate in the roe deer (13), or when they are impaired because of severe testiculopathies in humans (15, 18) .
In conclusion, our data provide important data on the dynamics of INSL3 during puberty, showing that, combined with previous animal data, INSL3 is under a stringent developmental control and is up-regulated during puberty under the differentiation action of LH on the Leydig cells. INSL3 has been suggested as a marker of Leydig cell status for clinical conditions associated with decreased testicular function or Leydig cell activity, such as male infertility of testicular origin or hypogonadism. INSL3 is therefore a promising marker also in pubertal disorders, such as premature and delayed puberty.
